FindTrial
Sign In

To quantifying atherogenic risk using atherogenic index of plasma and apolipoprotein A1 in subclinical hypothyroidism patients

ASSESSMENT OF ATHEROGENIC RISK USING ATHEROGENIC INDEX OF PLASMA AND APOLIPOPROTEIN A1 (APO A1) IN SUBCLINICAL HYPOTHYROIDISM - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089012
Enrollment
100
Registered
2025-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: E02- Subclinical iodine-deficiency hypothyroidism

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Vikram Yadav
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals diagnosed with subclinical hypothyroidism falling within the age group of 18 to 60 yrs

Exclusion criteria

Exclusion criteria: Overt hypothyroidism, hyperthyroidism, recent thyroid treatment, serious cardiovascular disease, lipid altering medicine, other metabolic disorder, pregnancy and lactation, recent surgery, chronic illness

Design outcomes

Primary

MeasureTime frame
Analyze the lipid profile and apo A1 in subclinical hypothyroidismTimepoint: 6 Months—

Secondary

MeasureTime frame
Assess the relationship between Apo A1 levels and cardiovascular risk factor in subclinical hypothyroidismTimepoint: 6 months—

Countries

India

Contacts

Public ContactVikram Yadav

RUHS college of medical sciences, jaipur

drjitendraahuja@yahoo.co.in8209033138

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026